Ibrutinib for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Treatment – 2014
Reading tools
Approved by the FDA on 12 February 2014, Imbruvica is used in previously treated patients diagnosed with Chronic Lymphocytic Leukemia.
Ibrutinib previously received FDA approval in 2013, in November, for Mantle Cell Lymphoma, a rare lymphoma. Binding to the active region of the small molecule BTK, it interferes with functions of B cells active in immunity. Nonclinical studies also indicate that it prevents proliferation of cancerous B cells. It causes the general side effects associated with most cancer drugs.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.